GO
Loading...

Pharmaceuticals

More

  • Mylan rejects Teva's $40.1 billion buyout offer Monday, 27 Apr 2015 | 9:58 AM ET

    NEW YORK— Mylan N.V. rejected Teva Pharmaceuticals' $40.1 billion buyout offer, saying the cash-and-stock proposal undervalues the company. Mylan is trying to buy Perrigo Co. of Ireland for about $30 billion in cash and stock, combining its own generic drug business with Perrigo's position in over-the-counter medications and other nonprescription...

  • April 27- The U.S. Food and Drug Administration should not consider an accelerated review for drugmaker Amgen Inc's marketing application for its skin cancer vaccine, FDA staff reviewers concluded in documents released on Monday. The review comes two days before a panel of FDA advisers votes on whether the treatment, a cancer-killing virus called talimogene...

  • NEW YORK, April 24- Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market, including drugs in short supply, according to industry experts and a Reuters review of regulatory filings. It is also pursuing a hostile takeover of drugmaker Perrigo Co Plc. Teva has already looked at the...

  • Mylan/Perrigo, a more likely combination: Pro   Friday, 24 Apr 2015 | 1:16 PM ET
    Mylan/Perrigo, a more likely combination: Pro

    Fred Hassan, Warburg Pincus Partner and Managing Director, discusses the latest pharmaceutical deals making headlines and believes Mylan and Perrigo are the most complementary for a deal.

  • Mylan to submit formal offer for Perrigo Friday, 24 Apr 2015 | 11:39 AM ET
    Mylan headquarters in Canonsburg, Pa.

    Mylan announced Friday morning that it had commenced a formal offer to acquire Perrigo for a mix of cash and stock.

  • NEW YORK— Generic drugmaker Mylan is making official its offer for over-the-counter medicines maker Perrigo as it remains at the center of a three-way battle: Mylan wants to buy Perrigo, while a larger rival wants to buy Mylan. Perrigo has already rejected Mylan's offer and reiterated Friday it feels the bid, worth more than $30 billion, is too low.

  • Mylan lowers price for Perrigo   Friday, 24 Apr 2015 | 10:37 AM ET
    Mylan lowers price for Perrigo

    CNBC's David Faber reports on pharmaceutical acquisitions making headlines including Mylan and Perrigo.

  • Epic battles brewing in pharma space   Friday, 24 Apr 2015 | 6:51 AM ET
    Epic battles brewing in pharma space

    CNBC's Meg Tirrell, and Jeremy Levin, Ovid Therapeutics CEO, survey the pharma landscape and discuss what's driving deal activity.

  • LONDON— Anglo-Swedish drug-maker AstraZeneca PLC reported a 7 percent fall in net profit for the first quarter of 2015, as cheaper copies of one of its best-sellers ate into sales. Chief Executive Pascal Soriot said AstraZeneca was bolstering its oncology division, with 72 trials of cancer drugs underway. AstraZeneca shares fell 2.4 percent to 47.13 pounds...

  • That has focused attention on other AbbVie drugs with blockbuster potential, including Viekira Pak, a new hepatitis C medication approved in the U.S. in December. But U.S. sales of $138 million in the first quarter came in below expectations of $215 million, on average, according to survey figures cited by analyst Robyn Karnauskas of Deutsche Bank.

  • April 23- U.S. drugmaker AbbVie Inc reported a better-than-expected quarterly profit and revenue, driven by strong sales of its arthritis drug, Humira. Sales of AbbVie's all-oral hepatitis C treatment Viekira Pak, approved by U.S. regulators in December, came in at $231 million. AbbVie raised its full-year adjusted profit forecast to $4.10- $4.30 per share, from...

  • Drugmaker AbbVie profit rises on sales of Humira Thursday, 23 Apr 2015 | 7:55 AM ET

    April 23- U.S. drugmaker AbbVie Inc reported a 4 percent rise in quarterly profit, driven by strong sales of its arthritis drug, Humira. The company's profit rose to $1.02 billion, or 63 cents per share, in the first quarter ended March 31, from $980 million, or 61 cents per share, a year earlier. On an adjusted basis, the company earned 94 cents per share.

  • LLY CFO: Here's what's driving profits   Thursday, 23 Apr 2015 | 7:39 AM ET
    LLY CFO: Here's what's driving profits

    Derica Rice, Eli Lilly CFO breaks down the company's quarterly results, and talks about products in the pipeline as some drugs come off patent.

  • The Indianapolis- based drugmaker posted a net profit of $529.5 million, or 50 cents per share, for the first quarter ended March 31, compared with a profit of $727.9 million, or 68 cents per share, a year earlier. In January, the company forecast full-year adjusted earnings of $3.10- $3.20 per share, and sales of $19.50- $20 billion. Lilly on Thursday cut its full-year...

  • INDIANAPOLIS— Eli Lilly and Co.' s first-quarter earnings tumbled 27 percent as generic competition continued to eat away at sales for key products, but the drugmaker's performance topped expectations. Overall, Lilly earned $529.5 million, or 50 cents per share, in the quarter that ended March 31. Analysts forecast, on average, earnings of 76 cents per share,...

  • Lilly profit falls 27 percent, hurt by strong dollar Thursday, 23 Apr 2015 | 6:32 AM ET

    April 23- Eli Lilly and Co reported a 27 percent fall in quarterly profit, hurt by a stronger dollar. The Indianapolis- based drugmaker posted a net profit of $529.5 million, or 50 cents per share, for the first quarter ended March 31, compared with a profit of $727.9 million, or 68 cents per share, a year earlier. Excluding items, the company earned 87 cents per share.

  • FRANKFURT, Germany— Swiss-based pharmaceutical company Novartis reported a large jump in first-quarter net profit Thursday as it recorded one-time gains from deals with other drug companies. Novartis sold its animal health business to Lilly. It also bought cancer drugs from GSK and sold its non-flu vaccines business, while Novartis and GSK combined their...

  • Vitamin Shoppe rises as Carlson Capital boosts stake Wednesday, 22 Apr 2015 | 4:11 PM ET

    NEW YORK— Shares of nutritional supplement seller Vitamin Shoppe jumped Wednesday after the asset management firm Carlson Capital said it has boosted its stake in the company. Carlson Capital LP disclosed ownership of about 1.6 million shares of Vitamin Shoppe, giving it a 5.3 percent stake in the company. In a form filed with the Securities and Exchange...

  • The love-hate triangle in pharma   Wednesday, 22 Apr 2015 | 2:09 PM ET
    The love-hate triangle in pharma

    Corey Davis, Canaccord Genuity, discusses big deals in pharmaceutical including Teva's bid for Mylan.

  • Abbott posts profit beat   Wednesday, 22 Apr 2015 | 2:07 PM ET
    Abbott posts profit beat

    CNBC's Meg Tirrell reports on Abbott Laboratories' earnings and deals associated with this company.